Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Regentis BiomaterialsRGNT -4.06%14 EV-to-OCF is -5.16 as of Aug. 09, 2026. GuruFocus rates RGNT with a GF Score™ of 14/100. The stock has 2 warning signs investors should review. Among 853 Medical Devices & Instruments companies, Regentis Biomaterials ranks better than 73.15% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Regentis Biomaterials's Enterprise Value is $7.09 Mil.
Regentis Biomaterials's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-1.38 Mil. Therefore, Regentis Biomaterials's EV-to-OCF for today is -5.16.
The historical rank and industry rank for Regentis Biomaterials's EV-to-OCF or its related term are showing as below:
RGNT'
s EV-to-OCF Range Over the Past 10 Years
Min: -5.16 Med: 0 Max: -5.16
Current: -5.16
During the past 6 years, the highest EV-to-OCF of Regentis Biomaterials was -5.16. The lowest was -5.16. And the median was .
RGNT's EV-to-OCF is ranked better than 73.15% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 7.82
vs RGNT: -5.16
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Regentis Biomaterials's PE Ratio (TTM) for today is calculated as:
Regentis Biomaterials's share price for today is $1.89.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Regentis Biomaterials's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-2.644.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Regentis Biomaterials's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regentis Biomaterials EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Regentis Biomaterials's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Regentis Biomaterials's EV-to-OCF falls into.
Regentis Biomaterials's current Enterprise Value is $7.09 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Regentis Biomaterials's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-1.38 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regentis Biomaterials (RGNT) has a EV-to-OCF of -5.16 as of Aug. 09, 2026. According to the industry distribution chart, Regentis Biomaterials ranks #229 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 26.8%.
Is Regentis Biomaterials' EV-to-OCF too high?
Regentis Biomaterials' current EV-to-OCF is -5.16. Based on the distribution chart, Regentis Biomaterials ranks #229 out of 853 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Regentis Biomaterials has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Regentis Biomaterials' EV-to-OCF compare to BNGO and ZJYL?
According to the Medical Devices & Instruments industry distribution chart, Regentis Biomaterials ranks #229 out of 853 companies for EV-to-OCF. This puts Regentis Biomaterials in the upper half of its industry. The industry median EV-to-OCF is 7.82. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.82, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regentis Biomaterials's current EV-to-OCF is -5.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regentis Biomaterials stock overvalued right now?
Regentis Biomaterials (RGNT) has a current EV-to-OCF of -5.16. The current EV-to-OCF is -5.16. Regentis Biomaterials' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Regentis Biomaterials (RGNT), the current EV-to-OCF is -5.16 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.
14GF Score
Get the complete analysis for RGNT
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGNT has been successfully added to your 
